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Genetic integrity in proliferating cells is guaranteed by the harmony of DNA replication,
appropriate DNA repair, and segregation of the duplicated genome. Breast cancer susceptibility
gene BRCA2 is a unique tumor suppressor that is involved in all three processes. Hence, it is
critical in genome maintenance. The functions of BRCA2 in DNA repair and homology-directed
recombination (HDR) have been reviewed numerous times. Here, I will brieﬂy go through the
functions of BRCA2 in HDR and focus on the emerging roles of BRCA2 in telomere homeostasis
and mitosis, then discuss how BRCA2 exerts distinct functions in a cell-cycle speciﬁc manner in
the maintenance of genomic integrity.
& 2014 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
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Individuals who inherit one defective copy of BRCA2 are predisposed
to early onset breast cancer [1]. BRCA2mutations are also associated
with the cancers in the ovary and pancreas [2]. The ﬁrst under-
standing of how BRCA2 disruption leads to early onset cancer
emerged from the analysis of mouse deﬁcient in Brca2 allele
(Brca2Tr/Tr) [3]. Cells from Brca2Tr/Tr mice exhibited hypersensitivity
to irradiation and the inter-strand DNA crosslinking agent, mitomy-
cin C. Metaphase chromosomes displayed chromosome breaks and
radial chromosomes, the hallmarks of defective double-strand break
(DSB) repair [3]. The ﬁnding that BRCA2 binds to Rad51 recombinase
through its conserved BRC repeats [4,5] and also at the C-terminus
[6] corroborated the involvement of BRCA2 in double strand break
(DSB) repair, through the regulation of Rad51 nucleoprotein ﬁlament
formation in HDR. The BRC repeats, a short stretch of repeated
sequences found in the exon 11, bind to Rad51 monomers and the
C-terminus binding stabilizes the oligomerization of Rad51 (Fig. 1)
[7,8]. In HDR, DSBs are ﬁrst resected and the resulting single
stranded DNAs (ssDNA) coated by Rad51 nucleoprotein ﬁlaments,
facilitating the ssDNA to invade into the homologous sister strand.
The invading ssDNA serves as a primer for DNA synthesis, using the
undamaged sister strand as the template, enabling the strand
exchange. Therefore, HDR is error-free. BRCA2 is crucial in ensuring
the intactness of HDR because it regulates both the strand invasion
and the appropriate stabilization/disassembly of the oligomerizedFig. 1 – Multiple functions of BRCA2 in cell cycle progression are il
sequence of human BRCA2, responsible for binding. The illustratio
reproduction of Min et al. [12], and the role of BRCA2 in M phase is
the Elsevier.Rad51 [8]. Thus, the absence of BRCA2 results in the accumulation of
DSBs and subsequent growth arrest [3].
Distinct from HDR, BRCA2 is also required for the ﬁtness of DNA
replication. In S phase, BRCA2 stabilizes Rad51 nucleoprotein
ﬁlaments and prevents fork reversal, thereby protecting the
nascent strands from resection by MRE11 nuclease [9]. The con-
served C-terminus of BRCA2 (aa 3251–3318 in human) is critical in
maintaining the ﬁdelity of replication, as stabilization of Rad51
ﬁlament is required for fork protection. Loading Rad51 on damaged
DNA was dispensable; therefore the protection of nascent replica-
tion tracks by BRCA2 is independent from its function in HDR. The
absence of Brca2 (mouse orthologue of human BRCA2) results in
the disappearance of typical Y-shaped DNA junctions at replication
forks in 2D-gels, consistent with the ﬁnding that BRCA2 inhibits
the breakdown of stalled replication forks [10].BRCA2 at the telomeres in S phase
Brca2-deﬁcient MEFs exhibit progressive telomere shortening and
end-to-end fusions. Telomere-FISH (Fluorescence in situ hybridi-
zation) analysis of Brca2-deﬁcient cells displayed common fragile
sites, reminiscent of defective replication at telomeres [11,12]. It
was shown that BRCA2 loads Rad51 to facilitate telomere replica-
tion [11]; prevents the stalled replication fork collapse, particu-
larly at the telomere lagging strand, in ATR-dependent manner
[12]. These functions at telomeres are consistent with the role oflustrated. Numbers below each protein denote the amino acid
n of BRCA2 at the telomere replication in S phase is the
the reproduction of Choi et al. [18], with the permission from
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meres are composed of TTAGGG repeats, which is capable of
forming secondary structures such as G-quadruplex, telomere
lagging strands can be more susceptible to fork stallings [13].
Brca2-deﬁcient MEFs exhibited telomere shortening and end-to-
end joining, because the replication forks stalled frequently at the
telomere lagging strand that were not protected.Fanconi anemia and the breast cancer susceptibility
Fanconi anemia (FA) is a rare recessive genetic disease character-
ized by aplastic anemia in childhood, susceptibility to leukemia
and cancer, with chromosome abnormalities. FA cells are hyper-
sensitive to inter-strand DNA crosslinking agents such as cisplatin
and mitotimycin C. There are 13 FA genes that participate in the
recognition and repair of damaged DNAs [14]. BRCA2-deﬁciency
shares common characteristics with FA: Brca2-deﬁcient MEFs
exhibit sensitivity to mitomycin C and exhibit radial structured
chromosomes [3]. Indeed, it was found that BRCA2 is also a FA
gene, FANCD1 [15]. BRCA2/FACD1 interacts with other FA gene
products including PALB2/FANCN [16]. As PABL2 links BRCA1 and
BRCA2 binding in DNA damage response [17], the two breast
cancer susceptibility genes that do not share any sequence
homology reconcile in the FA pathway and participate in HDR
(Fig. 1).Emerging roles of BRCA2 in mitosis
BRCA2-deﬁcient tumor cells also exhibit chromosome number
instability (aneuploidy). Aneuploidy results from unequal segre-
gation of chromosomes in mitosis. Because chromosomes are fully
packed in mitosis (M phase), DNA damage and repair are limited
at this stage. Therefore, there were implications that BRCA2 may
participate in the regulation of chromosome segregation.
Conditional deletion of Brca2 allele in MEFs (Brca2F11/F11; Fig. 2)
displayed unequal chromosome segregations in time-lapse microscopy,BRC 
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Fig. 2 – Top, BRCA2 functional domains and the sites phosphorylated
at the C-terminus are colored in yellow. Numbers denote the amino
motifs of mouse Brca2 and the targeting sites of mouse models indi
binding domain of BRCA2 [18], and Brca2F11 is a conditional knockosuggesting a more direct role of BRCA2 in mitosis. Indeed, BRCA2 binds
to BubR1, a critical component of spindle assembly checkpoint (SAC)
that ensures equal segregation of duplicated genomes in mitosis [18].
At the kinetochore, BRCA2 functions as a scaffold by bringing P/CAF
acetyltransferase to BubR1 and facilitates BubR1 acetylation and
modulates APC/C activity [18,19]. Inhibition of BRCA2–BubR1 interac-
tion in mice, by ectopic expression of the BubR1-binding domain of
Brca2, (mB2-9; Fig. 2) led to spontaneous tumorigenesis, without
perturbing HDR [18].
When the acetylation site of BubR1 is mutated to arginine in
mice, the mice develop spontaneous cancers just like the mice
deﬁcient in BRCA2-BubR1 binding [20], corroborating that the
acetylation of BubR1 is a tumor suppressive mechanism, innate in
BRCA2 function in vertebrates.
Depletion of BRCA2 is associated with multinucleation, indica-
tive of defects in cytokinesis. BRCA2 was found with Myosin II at
the midbody, suggesting that BRCA2 is involved in cytokinesis
[21], although the localization of BRCA2 at the midbody was
challenged due to the question of non-speciﬁcity of the antibody
against BRCA2 [22]. Then it was shown that Filamin A, an actin-
binding protein, binds to BRCA2 and recruits it to the midbody.
BRCA2 binds to CEP55 at the midbody and affects the recruitment
of ESCRT-associated proteins, Alix and Tsg101, thereby inﬂuencing
the abscission of cell cleavage [23]. Notably, the role of BRCA2 in
cytokinesis is regulated by Aurora B kinase [21] (Fig. 1). Taken
together, BRCA2 controls proper cell division, as well as the
ﬁdelity of DNA replication and repair in interphase.Domains, structure, mouse models of Brca2, and
human mutations
BRCA2 is a large protein of 400 kDa, composed of 27 exons.
Exon 11 of BRCA2 is uniquely large and consists of 8 BRC repeats
(Fig. 2). The crystal structure of BRC4 bound to Rad51 revealed
how BRCA2 controls the monomeric Rad51 to form nucleoprotein
ﬁlaments [24]. Downstream of BRC repeats, three oligonucleotide/
oligosaccharide-binding (OB) folds and a helix-turn-helix (HTH)repeat
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Table 1 – Characteristics of BRCA2 mutations in human cancer.
BRCA2 allele location Characteristics Reference
BRCA2 mutation in cancer patients One wt allele 373G4T MMC (mitomycin C)-sensitive [40]
Del ex 10-12 BRC repeat
1823_1825delA
3036_3039del4 BRC repeat
3374delA BRC repeat
3683T4G BRC repeat
6857delAA
7636delTT Helical domain
(HD)
8152_8154delT OB fold (OB1)
8297_8300insTT OB1
9254delATCAT OB fold (OB3)
9514G4T
Breast cancer families (data from Myriad genetic
laboratory)
One wt allele D2723H OB fold (OB2) HDR inactivated [41]
R3052W OB3
R2659K OB1
I2627F OB1
G2748D OB2
E2663V OB1
D2723G OB2
T2722R OB2
R2336H
R2659T OB1
L2653P OB1 Inconclusive
D3095E OB3
L2647P OB1
D2723A OB2
R2784W OB2
L2865V OB2
R2520Q HD, Dss1-binding
A2643G OB1
FA patients IVS19-1G4A IVS19-1G4A OB2 MMC-sensitive [15]
7691insAT 9900insA HD; TR2
3033delAAAC 10204A4T BRC repeat
IVS7þ2T4G IVS7þ2T4G MMC-sensitive; Acute Myeloid Leukemia (AML) [42]
8106G4C 204insA OB1
IVS7þ1G4A 5910C4G BRC repeat
IVS7þ2T4G 5146del4 BRC repeat
2816insA 1342C4A BRC repeat Brain Tumor, Wilms Tumor
886-
887delGT
8447T4A OB2
4876G4T 7757T4C BRC repeat; HD
6174delT 9435T4A BRC repeat; OB3
6174delT 886delGT BRC repeat
5301insA 7690T4C BRC repeat, HD
4150G4T 9424C4T BRC repeat; OB3
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binds to DSS1 protein, deleted in split-hand/split-foot syndrome.
Bound to DSS1, BRCA2 exerts binding to ssDNA. Hence, the 800
amino acids containing three OB folds and HTH motif was named
BRCA2DBD (DNA/DSS1-binding domain) (Fig. 1). The BRCA2DBD–
DSS1 structure implies that OB folds recognize ssDNA and the
HTH motif in dsDNA interaction, providing the explanation to
some extent, for the stimulation of BRCA2 in Rad51-mediated
HDR [25].
At the most C-terminus is the TR2 domain that stabilizes Rad51
nucleoprotein ﬁlament. Of note, Serine 3291 at this region is
phosphorylated by cyclin-dependent kinases (CDK). Phosphoryla-
tion of S3291 reduced BRCA2–Rad51 binding and was low in
S phase [26], indicative of cell cycle-dependent regulation of BRCA2
and Rad51 binding. However, another report argues that the
C-terminus of BRCA2 is not crucial in HDR but is involved in the
protection of replication forks [27]. TR2 domain, the C-terminus
critical for protecting replication forks, and the BubR1-binding
domain required for mitotic integrity all overlap in C-terminus (note
the amino acid numberings in Fig. 2.). However, the functions are
distinct particularly that BRCA2–BubR1 binding did not interfere
with HDR [18]. It is speculative that the functions of BRCA2 is
regulated differently in a cell cycle-dependent manner that the
C-terminus is involved in replication fork protection in S phase, HDR
in S/G2, and then binds to BubR1 in M phase. The code of multiple
phosphorylations including S3291 and others by CDK1, Plk1, Chk1,
Chk2 (Fig. 2), Aurora B kinases, etc. may be responsible (Fig. 1).
Several mouse models of Brca2 revealed the functions of BRCA2
[28]. Targeting sites of some of the representative mouse models
relevant to this review are illustrated in Fig. 2 (bottom). Brca2Tr/Tr
mice [29] and the Brca2Tr2014 mice [30] were the ﬁrst viable
knockout mice that developed thymic lymphomas in 12 weeks
after birth. These mice were targeted in exon 11 and the resultant
transcript harbored ﬁrst three BRC repeats [29] or 7 BRC repeats
(Fig. 2, bottom). It is interesting that the more BRC repeats left, the
viability increased (10% versus 20% in Brca2Tr/Tr and Brca2Tr2014
mice). Brca2/ or the Brca2Brglm1/Brglm1 mice that were targeted
at exon 10 exhibited early embryonic lethality.
Targeting exon 27 resulted in hypersensitivity to irradiation [31] or
DNA crosslinking agents with reduced life span [32]. Embryonic stem
cells from these mice (Brca2lex1/lex2) fail to protect stalled replication
forks, consistent with the notion that the stabilization of Rad51
nucleoprotein ﬁlament is required for replication fork protection.
Analyses on the BRCA2 mutation in somatic cancers are rare, and
the studies in BRCA2mutations are mostly from familial cancers. As
summarized in Table 1, BRCA2 mutations in Icelandic and Ashke-
nazi populations are large deletional mutations resulting in the loss
of most of the C-terminus, including BRC repeats and thereafter.
Similarly, Capan-1 pancreatic cancer cell line also shows deletion of
more than half of the C-terminus in one allele, and complete loss of
the other allele. In other breast cancer families and FA patients, the
types of mutations in the mutated BRCA2 allele are small deletions,
insertional, and missense mutations, most of them affecting BRC
repeats, OB folds, and/or helical domains. Consequently, the cells
exhibit sensitivity to MMC and HDR defects (Table 1). As the
functional studies of these mutations are far from complete, the
mutations associated with the defects in mitosis or cytokinesis is
not well deﬁned. However, Choi et al. [18] had reported that the
mutations of BRCA2 in human breast cancer patients that exhibited
problems in mitotic BubR1 acetylation were not restricted to the
E X P E R I M E N T A L C E L L R E S E A R C H 3 2 9 ( 2 0 1 4 ) 7 8 – 8 4 83BubR1-binding C-terminus, suggesting that not only the direct
binding site but modiﬁcations in other regions also play critical
roles in regulating mitosis. Similarly, conditional deletion of exon
11 in mice displayed problems in mitosis, although this region is
not directly related to BubR1 binding [18]. Therefore, the mutations
listed in Table 1 might also affect other functions of BRCA2.Coordinating multiple functions of BRCA2 in cell
cycle
BRCA2 plays multiple functions throughout the cell cycle (Fig. 1).
In response to DNA damage, Chk1 and Chk2 kinase phosphorylate
BRCA2 at the C-terminus and regulates the association with Rad51
[33]. Phosphorylation of S3291, which dissociates Rad51 ﬁla-
ments, takes place in G2 and promotes the entry into mitosis. In
addition to S3291, there are multiple phosphorylation sites at the
C-terminus that links the Rad51 disassembly to mitotic entry [34].
At the N-terminus, there are more serine and threonine residues
phosphorylated by CDK [26] (Fig. 2, top). DSB repair must be
suppressed before entry into mitosis, because active DSB repair in
mitosis will result in undesirable chromosome alterations [35].
CDK1 activation has shown to interfere with HDR [36]. Therefore,
phosphorylation of BRCA2 by CDK1 may participate in uncoupling
BRCA2's function from replication and HDR before entry into
mitosis.
Plk1 also phosphorylates BRCA2 at multiple sites, at the
N-terminus [37] and in exon 11 between BRC repeats [38]
(Fig. 2). DNA damage inhibits the phosphorylation by Plk1 and
is enhanced in cells progressing through G2/M. Therefore, the
phosphorylation of BRCA2 by Plk1 may alter the spectrum of
BRCA2 binding proteins, enabling BRCA2 to function in mitosis.
Consistent with this, Brca2F11/F11 MEFs (Fig. 2, bottom) exhibit
problems in chromosome segregation, although the P/CAF-inter-
acting N-terminus and the BubR1-interacting C-terminus of
BRCA2 are intact [18], suggesting that Plk1-dependent phosphor-
ylation at this central domain may play a role for BRCA2 to
execute function in mitosis. In mitotic exit, Aurora B associates
with, and probably phosphorylates, BRCA2 at the midbody, which
is likely to control cytokinesis [21]. Aurora A kinase has also been
implicated in BRCA2-associated cancers, and therefore is likely to
participate in the regulation of BRCA2 in cell cycle.Concluding remarks
Over the last two decades, efforts in BRCA2 research conﬁrmed
that it is a multifaceted protein, changing its partners and roles as
cells progress through the cell cycle. It is undoubtedly the most
important tumor suppressor in keeping the genome and chromo-
some intact. How BRCA2 is regulated in different cell cycle stages
and changes its localization to crucial sites are largely unknown
and awaits future investigation. The fact that one large tumor
suppressor BRCA2 exerts all these functions in different stages of
cell cycle may imply that BRCA2 coordinates all these discussed
functions to maintain genome integrity in vertebrates. Unveiling
the link will be most interesting, and may have clinical implica-
tions as well.Acknowledgments
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